Literature DB >> 21696648

Opioid dependence.

Jacinta O'Shea1, Fergus Law, Jan Melichar.   

Abstract

INTRODUCTION: Dependence on opioids is a multifactorial condition involving genetic and psychosocial factors. There are three approaches to treating opioid dependence. Stabilisation is usually by opioid substitution treatments, and aims to ensure that the drug use becomes independent of mental state (such as craving and mood) and independent of circumstances (such as finance and physical location). The next stage is to withdraw (detox) from opioids. The final aim is relapse prevention. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for stabilisation (maintenance) in people with opioid dependence? What are the effects of drug treatments for withdrawal in people with opioid dependence? What are the effects of drug treatments for relapse prevention in people with opioid dependence? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2008 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 23 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: buprenorphine; clonidine; lofexidine; methadone; naltrexone; and ultra-rapid withdrawal regimes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 21696648      PMCID: PMC2907824     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  23 in total

1.  Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins.

Authors:  Kenneth S Kendler; Kristen C Jacobson; Carol A Prescott; Michael C Neale
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

2.  A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months.

Authors:  Catherine McGregor; Robert Ali; Jason M White; Peter Thomas; Linda Gowing
Journal:  Drug Alcohol Depend       Date:  2002-09-01       Impact factor: 4.492

3.  A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway.

Authors:  A L Krook; O Brørs; J Dahlberg; K Grouff; P Magnus; E Røysamb; H Waal
Journal:  Addiction       Date:  2002-05       Impact factor: 6.526

4.  A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain.

Authors:  M Frischer; M Hickman; L Kraus; F Mariani; L Wiessing
Journal:  Addiction       Date:  2001-10       Impact factor: 6.526

Review 5.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Authors:  M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

6.  Thrice-weekly versus daily buprenorphine maintenance.

Authors:  R S Schottenfeld; J Pakes; P O'Connor; M Chawarski; A Oliveto; T R Kosten
Journal:  Biol Psychiatry       Date:  2000-06-15       Impact factor: 13.382

7.  The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results.

Authors:  Michael Gossop; John Marsden; Duncan Stewart; Tara Kidd
Journal:  Addiction       Date:  2003-03       Impact factor: 6.526

8.  Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia.

Authors:  Libby Topp; Carolyn Day; Louisa Degenhardt
Journal:  Drug Alcohol Depend       Date:  2003-06-05       Impact factor: 4.492

9.  Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients.

Authors:  Jamshid Ahmadi
Journal:  J Subst Abuse Treat       Date:  2003-04

10.  Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

Authors:  Sandra D Comer; Maria A Sullivan; Elmer Yu; Jami L Rothenberg; Herbert D Kleber; Kyle Kampman; Charles Dackis; Charles P O'Brien
Journal:  Arch Gen Psychiatry       Date:  2006-02
View more
  1 in total

1.  The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis.

Authors:  Moein Zangiabadian; Saeid Golmohammadi; Seyed Aria Nejadghaderi; Mohammad Mahdi Zahmatkesh; Mohammad Javad Nasiri; Majid Sadeghian
Journal:  Front Psychiatry       Date:  2022-09-26       Impact factor: 5.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.